Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc stock is traded at $15.17, with a volume of 80,857. It is up +3.55% in the last 24 hours and down -3.93% over the past month. Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.